Bicycle Therapeutics Stock Buy Hold or Sell Recommendation
| BCYC Stock | USD 20.40 0.05 0.25% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Bicycle Therapeutics is 'Strong Hold'. Macroaxis provides Bicycle Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BCYC positions.
Check out Bicycle Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide. In addition, we conduct extensive research on individual companies such as Bicycle and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Bicycle |
Execute Bicycle Therapeutics Buy or Sell Advice
The Bicycle recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bicycle Therapeutics. Macroaxis does not own or have any residual interests in Bicycle Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bicycle Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Bicycle Therapeutics Trading Alerts and Improvement Suggestions
| Bicycle Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 26.98 M. Net Loss for the year was (180.66 M) with loss before overhead, payroll, taxes, and interest of (67.15 M). | |
| Bicycle Therapeutics currently holds about 372.77 M in cash with (60.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.56. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update |
Bicycle Therapeutics Returns Distribution Density
The distribution of Bicycle Therapeutics' historical returns is an attempt to chart the uncertainty of Bicycle Therapeutics' future price movements. The chart of the probability distribution of Bicycle Therapeutics daily returns describes the distribution of returns around its average expected value. We use Bicycle Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bicycle Therapeutics returns is essential to provide solid investment advice for Bicycle Therapeutics.
| Mean Return | -0.07 | Value At Risk | -3.7 | Potential Upside | 4.68 | Standard Deviation | 4.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bicycle Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bicycle Stock Institutional Investors
| Shares | Camber Capital Management Llc | 2024-09-30 | 915 K | Ecor1 Capital, Llc | 2024-09-30 | 910 K | Point72 Asset Management, L.p. | 2024-09-30 | 899.8 K | Bnp Paribas Investment Partners Sa | 2024-06-30 | 888.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 798.5 K | Candriam Luxembourg S.c.a. | 2024-06-30 | 759.2 K | Woodline Partners Lp | 2024-06-30 | 586.6 K | Axa Sa | 2024-06-30 | 554.3 K | Parkman Healthcare Partners Llc | 2024-06-30 | 535.1 K | Baker Bros Advisors Lp | 2024-09-30 | 9.4 M | Deep Track Capital, Lp | 2024-09-30 | 3.5 M |
Bicycle Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.6M) | 4.2M | (4.8M) | (2.8M) | (2.5M) | (2.4M) | |
| Investments | (1.6M) | (1.2M) | (2.0M) | (19.0M) | (4.3M) | (4.5M) | |
| Change In Cash | 28.7M | 43.9M | 302.7M | (99.5M) | 187.8M | 197.2M | |
| Depreciation | 960K | 1.3M | 1.4M | 3.7M | 6.5M | 6.9M | |
| Capital Expenditures | 1.6M | 1.2M | 2.0M | 19.0M | 2.9M | 4.0M | |
| Net Income | (30.6M) | (51.0M) | (66.8M) | (112.7M) | (180.7M) | (171.6M) | |
| End Period Cash Flow | 92.1M | 136.0M | 438.7M | 339.2M | 527.0M | 553.3M | |
| Change To Netincome | 8.5M | 6.6M | 12.6M | 22.2M | 25.6M | 26.9M | |
| Free Cash Flow | (30.2M) | (19.0M) | (16.8M) | (105.1M) | (63.6M) | (60.4M) | |
| Other Non Cash Items | 5.4M | 751K | 2.1M | 442K | 746.8K | 1.3M |
Bicycle Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bicycle Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bicycle Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bicycle stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.27 | |
β | Beta against Dow Jones | 1.65 | |
σ | Overall volatility | 4.46 | |
Ir | Information ratio | -0.04 |
Bicycle Therapeutics Volatility Alert
Bicycle Therapeutics exhibits very low volatility with skewness of 4.26 and kurtosis of 27.07. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bicycle Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bicycle Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bicycle Therapeutics Fundamentals Vs Peers
Comparing Bicycle Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bicycle Therapeutics' direct or indirect competition across all of the common fundamentals between Bicycle Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bicycle Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bicycle Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bicycle Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bicycle Therapeutics to competition |
| Fundamentals | Bicycle Therapeutics | Peer Average |
| Return On Equity | -0.27 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Operating Margin | (23.86) % | (5.51) % |
| Current Valuation | 525.31 M | 16.62 B |
| Shares Outstanding | 47.55 M | 571.82 M |
| Shares Owned By Insiders | 1.29 % | 10.09 % |
| Shares Owned By Institutions | 92.37 % | 39.21 % |
| Number Of Shares Shorted | 3.52 M | 4.71 M |
| Price To Earning | (3.31) X | 28.72 X |
| Price To Book | 1.69 X | 9.51 X |
| Price To Sales | 38.08 X | 11.42 X |
| Revenue | 26.98 M | 9.43 B |
| Gross Profit | (67.15 M) | 27.38 B |
| EBITDA | (183.4 M) | 3.9 B |
| Net Income | (180.66 M) | 570.98 M |
| Cash And Equivalents | 372.77 M | 2.7 B |
| Cash Per Share | 12.56 X | 5.01 X |
| Total Debt | 44.96 M | 5.32 B |
| Debt To Equity | 0.15 % | 48.70 % |
| Current Ratio | 9.88 X | 2.16 X |
| Book Value Per Share | 12.04 X | 1.93 K |
| Cash Flow From Operations | (60.63 M) | 971.22 M |
| Short Ratio | 8.10 X | 4.00 X |
| Earnings Per Share | (3.28) X | 3.12 X |
| Target Price | 37.82 | |
| Number Of Employees | 284 | 18.84 K |
| Beta | 0.89 | -0.15 |
| Market Capitalization | 1.41 B | 19.03 B |
| Total Asset | 595.34 M | 29.47 B |
| Retained Earnings | (511.76 M) | 9.33 B |
| Working Capital | 492.33 M | 1.48 B |
| Current Asset | 103.53 M | 9.34 B |
| Current Liabilities | 8.46 M | 7.9 B |
Note: Disposition of 1109 shares by Travis Thompson of Bicycle Therapeutics at 9.82 subject to Rule 16b-3 [view details]
Bicycle Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bicycle . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bicycle Therapeutics Buy or Sell Advice
When is the right time to buy or sell Bicycle Therapeutics? Buying financial instruments such as Bicycle Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bicycle Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bicycle Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.28) | Revenue Per Share 0.716 | Quarterly Revenue Growth (0.50) | Return On Assets (0.15) | Return On Equity (0.27) |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.